Table 4.
STSG Success at 30 Days by Specific Anticoagulation/Antiplatelet Therapy
| Treatment | Aspirin | Clopidogrel | ||
|---|---|---|---|---|
| Status | Failure | Success | Failure | Success |
| + | 69 (43.67%) | 23 (41.82%) | 29 (18.35%) | 10 (18.18%) |
| - | 89 (56.33%) | 32 (58.18%) | 129 (81.65%) | 45 (81.82%) |
| χ2 = 0.057; df = 1; P = 0.811 | χ2 = 0.001; df = 1; P = 0.977 | |||
| Treatment | Warfarin | Xa-inhibitor | ||
| Status | Failure | Success | Failure | Success |
| + | 15 (9.49%) | 7 (12.73%) | 13 (8.23%) | 5 (9.09%) |
| - | 143 (90.51%) | 48 (87.27%) | 145 (91.77%) | 50 (90.91%) |
| χ2 = 0.461; df = 1; P = 0.4973 | χ2 = 0.039; df = 1; P = 0.8429 | |||
| Treatment | Enoxaparin | ASA/Clopidogrel (DAPT) | ||
| Status | Failure | Success | Failure | Success |
| + | 10 (6.33%) | 3 (5.45%) | 62 (88.57%) | 22 (95.65%) |
| - | 148 (93.67%) | 52 (94.55%) | 8 (11.43%) | 1 (4.35%) |
| Fisher; P = 1 | Fisher; P = 0.443 | |||
χ2(0.05) (df) = 3.841
Results of chi-square/Fisher exact test and descriptive statistics for STSG success at 30 days. Data are reported as n (column percentages).
Df = degrees of freedom, DAPT = dual antiplatelet therapy.